




Patent Docket P1096R1C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  T. Shantha Raju  Serial No.: 10/719,603  Filed: November 21, 2003  For: METHODS AND COMPOSITIONS FOR GALACTOSYLATED GLYCOPROTEINS	Group Art Unit: to be assigned  Examiner: to be assigned  Confirmation No: to be assigned  <b>Customer No: 09157</b>
<p style="text-align: center;"><b>CERTIFICATE OF EXPRESS MAILING</b></p> <p>Express Mail Number: <u>EV 351 931 998 US</u></p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450".</p> <p style="text-align: right;">February <u>19</u>, 2004  Mona Beltran</p>	

**TRANSMITTAL LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


Transmitted herewith are the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449;
3. Return postcard.

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

By:   
Elinor K. Shin  
Reg. No. 43,117  
Telephone No. (650) 225-3536

Date: February 19, 2004

# 149829



Patent Docket P1096R1C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of T. Shantha Raju Serial No.: 10/719,603 Filed: November 21, 2003 For: METHODS AND COMPOSITIONS FOR GALACTOSYLATED GLYCOPROTEINS</p>	<p>Group Art Unit: to be assigned Examiner: to be assigned Confirmation No: to be assigned CUSTOMER NO: 09157  <b>CERTIFICATE OF EXPRESS MAILING</b> Express Mail Number: EV 351 931 998 US I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450".  February <u>19</u>, 2004  Mona Beltran</p>
--	--

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

(X) **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

**37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) **or** a statement as specified in 37 CFR §1.97(e), as checked below.

**37 CFR §1.97(d)**

- after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) **and** a statement as specified in 37 CFR §1.97(e), as checked below.

(If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.)

- 37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- 37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified). Those patent(s) or publication(s) which are marked with an asterisk (\*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office in a prior application Serial No. 09/102,865, filed June 23, 1998 and relied upon in this application for an earlier filing date under 35 USC §120.

A concise explanation of relevance of the items listed on PTO-1449 is:

not given

- given for each listed item
- given for only non-English language listed item(s) (Required)
- in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

Date: February 19, 2004

By:   
Elinor K. Shin  
Reg. No. 43,117  
Telephone No. (650) 225-3536

# 149818

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1096R1C1	Serial No. 10/719603
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant T. Shantha Raju	
				Filing Date 21 Nov 2003	Group to be assigned

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
*	1	5,047,335	10.09.91	Paulson et al.			
*	2	5,096,816	17.03.92	Maiorella, B.			
*	3	5,116,964	26.05.92	Capon et al.			
*	4	5,180,674		Roth			
*	5	5,278,299	11.01.94	Wong et al.			
*	6	5,510,261	23.04.96	Goochee et al.			
*	7	5,565,335	15.10.96	Capon et al.			
*	8	5,610,297	11.03.97	Powers			
*	9	5,728,554		Bayer et al.			
*	10	5,834,251	10.11.98	Maras et al.			
*	11	6,165,745	26.12.00	Ward et al.			

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
*	12	WO 92/20798	26.11.92	PCT				
*	13	WO 94/11026	26.05.94	PCT				
*	14	WO 95/19181	20.07.95	PCT				
*	15	WO 95/23865	08.09.95	PCT				
*	16	WO 96/30046	03.10.96	PCT				
*	17	WO 97/30087	21.08.97	PCT				
*	18	WO 99/54342	28.10.99	PCT				

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*	19	Abraham et al., "p55 Tumor Necrosis Factor Receptor Fusion Protein in the Treatment of Patients With Severe Sepsis and Septic Shock" <u>Journal of the American Medical Assn.</u> 277:1531-1538 (1997)
*	20	Adler et al., "Impaired binding capacity of asialyl and agalactosyl IgG to Fc gamma receptors" <u>Clin. Exp. Rheumatol.</u> 13:315-319 (1995)
*	21	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin" <u>Proc. Natl. Acad. Sci.</u> 88:10535-10539 (1991)
*	22	Beale et al., "Structure and function of the constant regions of immunoglobulins" <u>Quarterly Reviews of Biophysics</u> 9:135-180 (1976)
*	23	Bodman, K.B. et al, "IgG glycosylation in autoimmune-prone strains of mice" <u>Clin. Exp. Immunol.</u> 95:103-107 (1994)
*	24	Boeggeman et al., "Expression of deletion constructs of bovine $\beta$ -1,4-galactosyltransferase in Escherichia coli: importance of Cys134 for its activity" <u>Protein Engineering</u> 6:779-785 (1993)
*	25	Bolt et al., "The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties" <u>European Journal of Immunology</u> 23:403-411 (1993)
*	26	Borman, "Carbohydrates' Complexities: Glycobiologists attain a more detailed understanding of the involvement of carbohydrates in intricate life processes" <u>C&amp;EN</u> 74:36-40 (1996)

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1096R1C1	Serial No. 10/719603
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b>  (Use several sheets if necessary)		Applicant T. Shantha Raju		
		Filing Date 21 Nov 2003	Group to be assigned	

**OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)**

* 27	Borys et al., "Ammonia Affects the Glycosylation Patterns of Recombinant Mouse Placental Lactogen-I By Chinese Hamster Ovary Cells in a pH-Dependent Manner" <u>Biotechnology and Bioengineering</u> 43(6):505-514 (Mar 15, 1994)
* 28	Borys et al., "Culture pH Affects Expression Rates and Glycosylation of Recombinant Mouse Placental Lactogen Proteins by Chinese Hamster Ovary (CHO) Cells" <u>Bio/Technology</u> 11:720-724 (Jun 1993)
* 29	Boyd et al., "The Effect of the Removal of Sialic Acid, Galactose and Total Carbohydrate on the Functional Activity of Campath-1H." <u>Molecular Immunology</u> 32:1311-1318 (1995)
* 30	Cant et al., "Glycosylation and functional activity of anti-D secreted by two human lymphoblastoid cell lines" <u>Cytotechnology</u> 15:223-228 (1994)
* 31	Carter et al., "Humanization of an Anti-p185HER2 Antibody For Human Cancer Therapy" <u>Proc. Natl. Acad. Sci. USA</u> 89:4285-4289 (May 1992)
* 32	Chatterjee et al., "Analysis of the Sequences of Human $\beta$ -1,4-Galactosyltransferase cDNA Clones" <u>Int. J. Biochem Cell. Biol.</u> 27:329-336 (1995)
* 33	Chotigeat et al., "Role of Environmental Conditions on the Expression Levels, Glycoform Pattern and Levels of Sialyltransferase for hFSH Produced by Recombinant CHO cells" <u>Cytotechnology</u> 15:217-221 (1994)
* 34	Chuang et al., "Elimination of N-linked glycosylation sites from the human IgA1 constant region: effects on structure and function" <u>Journal of Immunology</u> 158:724-732 (1997)
* 35	Cox et al., "Effect of Media Composition on the Induction of Chorionic Gonadotropin by Sodium Butyrate in HeLa Cells" <u>In Vitro</u> 19(1):1-6 (1983)
* 36	Donadel et al., "Human polyreactive and monoreactive antibodies: effect of glycosylation on antigen binding" <u>Glycobiology</u> 4:491-496 (1994)
* 37	Duncan and Winter., "The Binding Site for Clq on IgG." <u>Nature</u> . 332(21):738-740 (Apr 1988)
* 38	Dwek et al., "Glycobiology: 'the function of sugar in the IgG molecule'" <u>Journal of Anatomy</u> 187:279-292 (Oct 1995)
* 39	Edelman et al., "The covalent structure of an entire $\gamma$ G immunoglobulin molecule" <u>Proc. Natl. Acad. Sci. USA</u> 63:78-85 (1969)
* 40	Fischer et al., "Reduction of Graft Failure by a Monoclonal Antibody (Anti-LFA-1 CD11a) After HLA Nonidentical Bone Marrow Transplantation in Children with Immunodeficiencies, Osteopetrosis, and Fanconi's Anemia" <u>Blood</u> 77(2):249-256 (January 15, 1991)
* 41	Furukawa et al., "Kinetic study of a galactosyltransferase in the B cells of patients with rheumatoid arthritis" <u>International Immunology</u> 2(1):105-112 (1990)
* 42	Gazzano-Santoro et al., "A Non-Radioactive Complement-Dependent Cytotoxicity Assay for Anti-CD20 Monoclonal Antibody." <u>Journal of Immunological Methods</u> . 202:163-171 (1997)
* 43	Goochée et al., "The Oligosaccharides of Glycoproteins: Bioprocess Factors Affecting Oligosaccharide Structure and Their Effect on Glycoprotein Properties" <u>Bio/Technology</u> 9:1347-1355 (1991)
* 44	Goochée et al., "The Oligosaccharides of Glycoproteins: Factors Affecting Their Synthesis and Their Influence on Glycoprotein Properties" <u>Frontiers in Bioprocessing II</u> , Todd et al., eds., American Chemical Society pps. 199-240 (1992)
* 45	Harris et al., "Refined Structure of an Intact IgG2a Monoclonal Antibody" <u>Biochemistry</u> 36:1581-1597 (1997)
* 46	Hart, "Glycosylation" <u>Current Opinion in Cell Biology</u> 4:1017-1023 (1992)

Examiner	Date Considered
----------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1096R1C1	Serial No. 10/719603
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant T. Shantha Raju		
		Filing Date 21 Nov 2003	Group to be assigned	
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>				
* 47	Hayter et al., "Glucose-Limited Chemostat Culture of Chinese Hamster Ovary Cells Producing Recombinant Human Interferon- $\gamma$ " <u>Biotechnology and Bioengineering</u> 39:327-335 (1992)			
* 48	Hearing et al., "Isolation of Chinese Hamster Ovary Cell Lines Temperature Conditional for the Cell-Surface Expression of Integral Membrane Glycoproteins" <u>The Journal of Cell Biology</u> 108:339-353 (1989)			
* 49	Herrmann et al., "Large-Scale Production of a Soluble Human $\beta$ -1,4-Galactosyltransferase Using a <i>Saccharomyces cerevisiae</i> Expression System" <u>Protein Expr. Purif.</u> 6:72-78 (1995)			
* 50	Hourmant et al., "Administration of an Anti-CD11a Monoclonal Antibody in Recipients of Kidney Transplantation" <u>Transplantation</u> 58(3):377-380 (August 1994)			
* 51	Hsu et al., "A Comparative Study of the Peroxidase-antiperoxidase Method and an Avidin-biotin Complex Method for Studying Polypeptide Hormones with Radioimmunoassay Antibodies" <u>Am. J. Clin. Path.</u> 75(5):734-738 (May 1981)			
* 52	Hsu et al., "Differential N-Glycan Patterns of Secreted and Intracellular IgG Produced in <i>Trichoplusia ni</i> Cells" <u>The Journal of Biological Chemistry</u> 272:9062-9070 (1997)			
* 53	Iwase et al., "Estimation of the Number of O-Linked Oligosaccharides per Heavy Chain of Human Serum IgA1 by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOFMS) Analysis of the Hinge Glycopeptide" <u>J. Biochemistry</u> 120:393-397 (1996)			
* 54	Jeffeiris et al., "Glycosylation of Antibody Molecules: Structural and Functional Significance" <u>Antibody Engineering</u> 65:111-128 (1997)			
* 55	Jeffeiris et al., "Recognition sites on human IgG for Fc $\gamma$ receptors: the role of glycosylation" <u>Immunology Letters</u> 44:111-117 (1995)			
* 56	Jenkins et al., "Getting the glycosylation right: Implications for the biotechnology industry" <u>Nature Biotechnology</u> 14:975-981 (1996)			
* 57	Kaminski et al., "Radioimmunotherapy of B-cell Lymphoma with [ <sup>131</sup> I]Anti-B1 (Anti-CD20) Antibody" <u>New England J. of Medicine</u> 329:459-465 (1993)			
* 58	Kim et al., "The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies" <u>Growth Factors</u> 7(1):53-64 (1992)			
* 59	Klama et al., "The Abnormalities in the Glycosylation of IgG" <u>Reumatologia</u> 34(1):26-30 (1996)			
* 60	Kleene et al., "Expression of Soluble Active Human $\beta$ 1,4 Galactosyltransferase in <i>Saccharomyces cerevisiae</i> " <u>Biochem. &amp; Biophys. Res. Comm.</u> 201:160-167 (1994)			
* 61	Kotz et al., "Immunoglobulin G galactosylation deficiency determined by isoelectric focusing and lectin affinoblotting in differential diagnosis of rheumatoid arthritis" <u>Electrophoresis</u> 17:533-534 (1996)			
* 62	Kumpel et al., "Galactosylation of Human IgG Monoclonal Anti-D Produced by EBV-transformed B-lymphoblastoid Cell Lines is Dependent on Culture Method and Affects Fc Receptor-mediated Functional Activity" <u>Hum. Antibod. Hybridomas</u> 5:143-151 (1994)			
* 63	Le Gros et al., "The Effects of Sodium Butyrate on Lymphokine Production" <u>Lymphokine Research</u> 4(3):221-227 (1985)			
* 64	Lifely et al., "Glycosylation and Biological Activity of CAMPATH-1H Expressed in Different Cell Lines and Grown Under Different Culture Conditions." <u>Glycobiology</u> 5(8):813-822 (Dec 1995)			
* 65	Liu et al., "Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity" <u>J. Immunol.</u> 139:3521-3526 (1987)			
* 66	Malhotra et al., "Glycosylation Changes of IgG Associated with Rheumatoid Arthritis Can Activate Complement Via the Mannose-Binding Protein" <u>Nat. Med.</u> 1:237-243 (1995)			
Examiner		Date Considered		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1096R1C1	Serial No. 10/719603
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant T. Shantha Raju		
		Filing Date 21 Nov 2003	Group to be assigned	
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>				
* 67	Maloney et al., "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDE-C2B8) in Patients With Recurrent B-Cell Lymphoma" <u>Blood</u> 84:2457-2466 (1994)			
* 68	McLaughlin et al., "Preliminary Report on a Phase III Pivotal Trial of the Anti-CD20 Antibody (MAB) IDE-C2B8 in Patients (PTS) with Relapsed Low-Grade or Follicular Lymphoma (LG/F NHL)" <u>Proc. Am. Soc. Clin. Oncol.</u> 15:417 (1996)			
* 69	Mizutani et al., "High Glucose and Hyperosmolarity Increase Platelet-derived Growth Factor mRNA Levels in Cultured Human Vascular Endothelial Cells" <u>Biochemical and Biophysical Research Communications</u> 187(2):664-669 (1992)			
* 70	Morin et al., "cDNA of the immunoglobulin κ chain of an Epstein-Barr virus-transformed human lymphoid cell line: Partial sequence determination and bacterial expression" <u>Proc. Natl. Acad. Sci. USA</u> 82:7025-7029 (Oct 1985)			
* 71	Mulkerin et al., "Antibody-Mediated Cell Killing Depends Upon the Structure of the CH <sub>2</sub> Oligosaccharide" (Abstract for the Well-Characterized Biologicals meeting in San Francisco) (Jan 1998)			
* 72	Newkirk, M.W. et al., "Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice" <u>Clin. Exp. Immunol.</u> 106:259-264 (1996)			
* 73	Ohlson et al., "Use of monoclonal antibodies for weak affinity chromatography" <u>Journal of Chromatography A</u> 758:199-208 (1997)			
* 74	Parekh et al., "Age-related galactosylation of the N-linked oligosaccharides of human serum IgG" <u>Journal of Experimental Medicine</u> 167:1731-1736 (1988)			
* 75	Parekh et al., "Cell-Type-Specific and Site-Specific N-Glycosylation of Type I and Type II Human Tissue Plasminogen Activator" <u>Biochemistry</u> 28:7644-7662 (1989)			
* 76	Parekh, "Effects of Glycosylation on Protein Function" <u>Current Opinion in Structural Biology</u> 1:750-754 (1991)			
* 77	Parekh, R.B. et al., "Association of Rheumatoid Arthritis and Primary Osteoarthritis with Changes in the Glycosylation Pattern of Total Serum IgG." <u>Nature</u> 316:452-457 (1985)			
* 78	Park et al., "Enhanced β-Galactosidase Production by High Cell-Density Culture of Recombinant <i>Bacillus subtilis</i> with Glucose Concentration Control" <u>Biotechnology and Bioengineering</u> 40:686-696 (1992)			
* 79	Press et al., "Radiolabeled-antibody Therapy of B-cell Lymphoma with Autologous Bone Marrow Support" <u>New England J. of Medicine</u> 329:1219-1224 (1993)			
* 80	Presta et al., "Humanization of an Antibody Directed Against IgE" <u>J. Immunol.</u> 151(5):2623-2632 (September 1, 1993)			
* 81	Provencher et al., "Estimation of Globular Protein Secondary Structure from Circular Dichroism" <u>Biochemistry</u> 20:33-37 (1981)			
* 82	Rademacher et al., "Re: Conservation and evolution of glycosylation sites on immunoglobulin-type domains" <u>Glycobiology</u> 3:418-419 (1993)			
* 83	Raju et al., "Biological significance and structural features of immunoglobulin glycoforms" <u>ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY</u> (Abstract No. 024) vol. 215 (Apr 29, 1998)			
* 84	Raju et al., "Glycopinopin: biological significance and methods for the analysis of complex carbohydrates of recombinant glyccoproteins" <u>Biotechnology &amp; Applied Biochemistry</u> 24(Pt 3):191-194 (Dec 1996)			
* 85	Schwientek et al., "Efficient intra- and extracellular production of human β-1,4-galactosyltransferase in <i>Saccharomyces cerevisiae</i> is mediated by yeast secretion leaders" <u>Gene</u> 145:299-303 (1994)			
* 86	Sheeley et al., "Characterization of Monoclonal Antibody Glycosylation: Comparison of Expression Systems and Identification of Terminal α-Linked Galactose" <u>Analytical Biochemistry</u> 247:102-110 (1997)			
Examiner		Date Considered		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1096R1C1	Serial No. 10/719603
LIST OF DISCLOSURES CITED BY APPLICANT  (Use several sheets if necessary)		Applicant T. Shantha Raju		
		Filing Date 21 Nov 2003	Group to be assigned	
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>				
* 87	St. John et al., "Immunologic Therapy for ARDS, Septic Shock, and Multiple-Organ Failure" <u>Chest</u> 103:932-943 (1993)			
* 88	Stoppa et al., "Anti-LFA1 Monoclonal Antibody (25.3) for Treatment of Steroid-resistant Grade III-IV Acute Graft-versus-host Disease" <u>Transplant International</u> 4:3-7 (1991)			
* 89	Tsuchiya et al., "Effects of Galactose Depletion from Oligosaccharide Chains on Immunological Activities of Human IgG" <u>The Journal of Rheumatology</u> 16:285-290 (1989)			
* 90	Umana et al., "A mathematical model of N-linked glycoform biosynthesis" <u>Biotechnology and Bioengineering</u> 55(6):890=908 (Sep 20, 1997)			
* 91	Weitzhandler et al., "Analysis of Carbohydrates on IgG Preparations" <u>Journal of Pharmaceutical Sciences</u> 83:1670-1675 (1994)			
* 92	Werner et al., "Mammalian Cell Cultures, Part I: Characterization, morphology and metabolism" <u>Arzneim.-Forsch./Drug Res.</u> 43 (II)(10):1134-1139 (1993)			
* 93	Werner et al., "Mammalian Cell Cultures, Part II: Genetic Engineering, Protein Glycosylation, Fermentation and Process Control" <u>Arzneim.-Forsch./Drug Res.</u> 43(11):1242-1249 (1993)			
* 94	Wittwer et al., "Glycosylation at Asn-184 Inhibits the Conversion of Single-Chain to Two-Chain Tissue-Type Plasminogen Activator by Plasmin" <u>Biochemistry</u> 29:4175-4180 (1990)			
* 95	Wormald et al., "Variations in Oligosaccharide-Protein Interactions in Immunoglobulin G Determine the Site-Specific Glycosylation Profiles and Modulate the Dynamic Motion of the Fc Oligosaccharides" <u>Biochemistry</u> 36:1370-1380 (1997)			
* 96	Wright and Morrison, "Effect of altered CH <sub>2</sub> -associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1" <u>Journal of Experimental Medicine</u> 180(3):1087-1096 (Sep 1, 1994)			
* 97	Wright and Morrison, "Effect of Glycosylation on Antibody Function: Implications for Genetic Engineering." <u>Trends in Biotechnology</u> 15:26-32 (Jan 1997)			
* 98	Wyss et al., "The structural role of sugars in glycoproteins" <u>Current Opinion in Biotechnology</u> 7:409-416 (1996)			
* 99	Yamada et al., "Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum" <u>Glycoconjugate Journal</u> 14:401-405 (1997)			
*100	Youings, Adrian et al, "Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients" <u>Biochemical Journal</u> 314:621-630 (1996)			
Examiner		Date Considered		
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>				